FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3110855605> ?p ?o ?g. }

• W3110855605 endingPage "S732" @default.
• W3110855605 startingPage "S731" @default.
• W3110855605 abstract "CF is a rare, multi-systemic genetic disease characterized by impaired survival and reduced health-related quality-of-life (HRQoL). The CFQ-R-8D (Acaster NACFC 2019) is a disease-specific preference-based scoring algorithm that estimates utilities based on a standard, well-validated HRQoL instrument in CF (CFQ-R). The CFTR modulator ELX/TEZ/IVA provided substantial improvements in lung function (measured by ppFEV1) and CFQ-R respiratory symptom domains in a registrational trial enrolling people with CF (pwCF) aged ≥12 years with F508del/minimal function (F/MF) genotypes (NCT03525444). Here we applied the CFQ-R-8D to estimate utility benefit in pwCF not previously eligible for CFTR modulators treated with ELX/TEZ/IVA, including benefit beyond that explained by lung function. The CFQ-R-8D algorithm was used to calculate health-state utilities from CFQ-R data collected in participants aged ≥14 years in NCT03525444, a 24-week, placebo-controlled study. A mixed effects model for repeated measures (MMRM) was used to estimate the utility benefit of ELX/TEZ/IVA in pwCF using CFQ-R-8D data from Week 4 and beyond. Utility benefit was estimated with and without controlling for ppFEV1, measured at time of CFQ-R-8D assessment (categorical variable: ≥70% vs <70%). Average CFQ-R-8D utility at baseline was 0.81 (on a 0.00 to 1.00 scale) in both ELX/TEZ/IVA and placebo cohorts. By Week 4, average utility increased 0.07 among pwCF receiving ELX/TEZ/IVA and decreased 0.01 among those receiving placebo. Without adjusting for ppFEV1, ELX/TEZ/IVA provided an estimated utility benefit of 0.083 (p<0.001) versus placebo measured across Weeks 4 to 24. Controlling for ppFEV1, the estimated utility benefit was 0.079 (p<0.001). Meaningful utility improvements in pwCF with F/MF genotypes were achieved by Week 4 after initiating ELX/TEZ/IVA and are consistent with improvements observed over the subsequent 20 weeks of treatment. Utility benefit was demonstrated even after controlling for ppFEV1, suggesting ELX/TEZ/IVA confers substantial HRQoL benefits beyond those mediated by improvement in ppFEV1." @default.
• W3110855605 created "2020-12-21" @default.
• W3110855605 creator A5012122740 @default.
• W3110855605 creator A5023741009 @default.
• W3110855605 creator A5032440181 @default.
• W3110855605 creator A5039857883 @default.
• W3110855605 creator A5056247736 @default.
• W3110855605 creator A5065797375 @default.
• W3110855605 creator A5087880538 @default.
• W3110855605 date "2020-12-01" @default.
• W3110855605 modified "2023-09-27" @default.
• W3110855605 title "PRS77 Application of the Cfq-R-8D to Estimate Utility Benefit of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in People with Cystic Fibrosis (CF)" @default.
• W3110855605 doi "https://doi.org/10.1016/j.jval.2020.08.1957" @default.
• W3110855605 hasPublicationYear "2020" @default.
• W3110855605 type Work @default.
• W3110855605 sameAs 3110855605 @default.
• W3110855605 citedByCount "1" @default.
• W3110855605 countsByYear W31108556052022 @default.
• W3110855605 crossrefType "journal-article" @default.
• W3110855605 hasAuthorship W3110855605A5012122740 @default.
• W3110855605 hasAuthorship W3110855605A5023741009 @default.
• W3110855605 hasAuthorship W3110855605A5032440181 @default.
• W3110855605 hasAuthorship W3110855605A5039857883 @default.
• W3110855605 hasAuthorship W3110855605A5056247736 @default.
• W3110855605 hasAuthorship W3110855605A5065797375 @default.
• W3110855605 hasAuthorship W3110855605A5087880538 @default.
• W3110855605 hasBestOaLocation W31108556051 @default.
• W3110855605 hasConcept C126322002 @default.
• W3110855605 hasConcept C142724271 @default.
• W3110855605 hasConcept C204787440 @default.
• W3110855605 hasConcept C27081682 @default.
• W3110855605 hasConcept C2776502428 @default.
• W3110855605 hasConcept C2776938444 @default.
• W3110855605 hasConcept C2777714996 @default.
• W3110855605 hasConcept C2778428886 @default.
• W3110855605 hasConcept C3018587741 @default.
• W3110855605 hasConcept C71924100 @default.
• W3110855605 hasConceptScore W3110855605C126322002 @default.
• W3110855605 hasConceptScore W3110855605C142724271 @default.
• W3110855605 hasConceptScore W3110855605C204787440 @default.
• W3110855605 hasConceptScore W3110855605C27081682 @default.
• W3110855605 hasConceptScore W3110855605C2776502428 @default.
• W3110855605 hasConceptScore W3110855605C2776938444 @default.
• W3110855605 hasConceptScore W3110855605C2777714996 @default.
• W3110855605 hasConceptScore W3110855605C2778428886 @default.
• W3110855605 hasConceptScore W3110855605C3018587741 @default.
• W3110855605 hasConceptScore W3110855605C71924100 @default.
• W3110855605 hasLocation W31108556051 @default.
• W3110855605 hasOpenAccess W3110855605 @default.
• W3110855605 hasPrimaryLocation W31108556051 @default.
• W3110855605 hasRelatedWork W2018066050 @default.
• W3110855605 hasRelatedWork W2025650618 @default.
• W3110855605 hasRelatedWork W2037194719 @default.
• W3110855605 hasRelatedWork W2413703802 @default.
• W3110855605 hasRelatedWork W2806420269 @default.
• W3110855605 hasRelatedWork W4252944256 @default.
• W3110855605 hasRelatedWork W4281618394 @default.
• W3110855605 hasRelatedWork W4281707926 @default.
• W3110855605 hasRelatedWork W4281728547 @default.
• W3110855605 hasRelatedWork W4379981181 @default.
• W3110855605 hasVolume "23" @default.
• W3110855605 isParatext "false" @default.
• W3110855605 isRetracted "false" @default.
• W3110855605 magId "3110855605" @default.
• W3110855605 workType "article" @default.